A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose - Wikidata - wikimedia - TriplyDB

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

http://www.wikidata.org/entity/Q28475004

about

Chapter 7: Pharmacogenomics Cancer pharmacogenomics: strategies and challenges Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Cardiovascular pharmacogenomics: current status and future directions Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics Pharmacogenetics and anaesthesia: the value of genetic profiling Pharmacogenomics discovery and implementation in genome-wide association studies era Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer Warfarin pharmacogenetics: does more accurate dosing benefit patients?Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis Progress in pharmacogenetics: consortiums and new strategies Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups Warfarin Pharmacogenetics: New Life for an Old Drug Systems genetics: the added value of gene expression Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene Automatic filtering and substantiation of drug safety signals Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information.Genome-wide discovery of drug-dependent human liver regulatory elements Genome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide Antimicrobials A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population Identifying Loci Contributing to Natural Variation in Xenobiotic Resistance in Drosophila Genome-wide association studies and beyond Genome at juncture of early human migration: a systematic analysis of two whole genomes and thirteen exomes from Kuwaiti population subgroup of inferred Saudi Arabian tribe ancestry.A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians

P2860

Q21563496-10E8843B-C2CC-4092-88E5-039846E701FA Q24289309-C6460EC3-F44E-42D7-8B9C-4A7ABEA02CA4 Q24311573-48E769BE-EEB2-4BAC-9DF6-DA43E2D88912 Q24631841-69244513-0F31-4F46-B4D2-D2B497171BE5 Q24641999-58F96CCB-FBAD-491E-81E3-6E7BDF3618A2 Q26787099-FA215996-6C20-4440-B88A-2C37A5CB4D37 Q26801183-CE37EB61-67DD-40B6-BA63-DA4BA3598531 Q26822796-84C86817-1C60-4AED-BEFC-7257A5487AB8 Q26823542-525FD5F0-9A2A-4B72-B634-61C61F6176DD Q26827814-3436D6B4-C5C4-406E-987B-CE4DAAAB64C3 Q26859221-2EF06D1A-FA82-4093-AFF0-ECB46622E476 Q27001573-3AB11665-FA63-4950-B931-D1C6031CF0B3 Q27002899-6EF2B827-628F-4561-BFAC-9CF304125512 Q27006860-DF729D8B-55BB-4EE2-ACC2-5FD3AE092F41 Q27011524-49F97A1F-01DF-4ED2-ABF6-A7528FAE2E02 Q27026134-5BFE9E91-4168-43D4-971A-4E027755EAB4 Q27026358-286E112C-05FB-49BE-BF15-55F3C3802A69 Q27027304-3EC45858-0A48-476C-9A89-A8C5D1CEE4F3 Q27334876-3C0CA06A-0F49-4BED-BA87-02110B3BBBC6 Q27692687-2C8162B6-7C43-4730-A904-25B542EE6486 Q28071310-858ED047-449C-405E-9160-654F2E8AE758 Q28071652-BA313B5F-4D55-4E33-9A64-B235713EEFEC Q28083100-6D5D3ECD-7BCE-413B-9888-A367515B9AA8 Q28276514-38DD32E6-546D-4B19-9286-BCD46FD956B4 Q28395337-B5FF109E-0445-4FFC-B816-1EE0294EE8DA Q28468726-A973F3A0-5993-4471-9EFD-55A8A9CF656B Q28474166-77C4E49B-3EB5-4050-B120-D52BA12EAA81 Q28477763-07605C17-E560-477F-B6B0-4EEBD5117B60 Q28481005-11EB737D-50F2-4276-8468-1B6D3ED1AF93 Q28482131-43AA95EB-EDD9-4E4E-AF85-B7693CC2CA1D Q28483861-9DD516ED-D7BE-4663-89DF-6CFAD97350E0 Q28484480-9334A12A-260F-433E-B255-3286EB3E9999 Q28543477-659941EF-A999-4804-98B3-A138368E6BBA Q28550088-DB08A3F4-6712-428D-ABB8-8995E8A01C39 Q28550740-C80B89A8-54AE-41B1-A4AF-09ECD019F385 Q28551192-5AE1FE48-E9AE-47DC-A715-F82FA4055DD5 Q28658449-15D957C0-3E58-4EAA-BAFC-8197FCBDFC6A Q30437010-B6AB1F6A-CB6C-4988-9064-24D1963E7BEA Q30568150-924F0427-2DCB-4928-B40E-EA78516CB400 Q31016306-7FD56780-F591-4963-A0E1-06264FE9A2F7

P2860

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

http://www.wikidata.org/entity/Q28475004

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A genome-wide association stud ...... determinants of warfarin dose

@ast

A genome-wide association stud ...... determinants of warfarin dose

@en

A genome-wide association stud ...... determinants of warfarin dose

@nl

type

label

A genome-wide association stud ...... determinants of warfarin dose

@ast

A genome-wide association stud ...... determinants of warfarin dose

@en

A genome-wide association stud ...... determinants of warfarin dose

@nl

prefLabel

A genome-wide association stud ...... determinants of warfarin dose

@ast

A genome-wide association stud ...... determinants of warfarin dose

@en

A genome-wide association stud ...... determinants of warfarin dose

@nl

P1433

Q28475004-C8F8AE19-C772-421C-A3F4-FA1D2FFAF350

P1476

Q28475004-F11AEFD8-8C01-467F-9276-F1CC1358C67C

P2093

Q28475004-19AC22A9-1F89-4E4B-B601-E7DF9BD19110

Q28475004-28E0BD3D-3BEE-4F46-A1C4-2E237E9AB17D

Q28475004-2E1FAE4E-ACB8-4D7E-995A-07B5CC1F482E

Q28475004-573FA668-435C-4F2E-93AF-FC98ABFAF6DA

Q28475004-7BA1F85E-B647-475C-8C38-6F3BB1F28F65

Q28475004-A5D41AA4-1955-4647-A66F-EEBC75245F64

Q28475004-C4589E85-7812-4FB3-A1CD-F45B91A00A7F

Q28475004-EB0C1D80-C229-48F9-A2F8-47B654E91F08

Q28475004-ED543907-7787-4BC1-B2AA-B5DD8FDAA070

P2860

Q28475004-07AF5169-8BEE-40B8-ACDB-4A565F2899A4

Q28475004-0D6862C7-75A7-43C2-A798-93AFB025372F

Q28475004-16A3367E-510D-4B18-9A54-5BDC94012932

Q28475004-1891A699-1B34-44DC-B140-8AD2317489E0

Q28475004-19B7DC0F-2527-47A3-83BE-891012F6686F

Q28475004-289DF3A0-862B-4CB0-8CD3-241D8D4A04C1

Q28475004-321EEF16-8E02-4C36-BD00-0590C2CA1856

Q28475004-35120959-73B4-4E3B-BA93-C046FF2EAE51

Q28475004-39085C3E-86EB-4896-86CD-FC1340E39440

Q28475004-3AE41E34-B185-42CD-A031-E17FFA11073C

P304

Q28475004-9BDEF921-2B96-4752-8FE0-57D40C1B12F8

P31

Q28475004-C7B673D2-CF82-417A-B8B4-9402B6CA9D47

P3181

Q28475004-80D1CA3E-7E9D-4FC3-B805-F1EEF04E8805

P356

Q28475004-B3E21A7B-2C95-499A-BD04-666BF1533E3C

P407

Q28475004-8A2AABEB-D47A-4F59-B336-A3DE26A3AA57

P433

Q28475004-801D6E34-786C-41A8-9DBA-DBD0EDB92F01

P478

Q28475004-72D222E4-2CA5-433A-A6DF-FF27EF760615

P50

Q28475004-7E869781-1723-4363-B497-B827C9F2B840

Q28475004-837BFE95-4B5A-4ADE-BBFD-9A45B3FB490B

Q28475004-95BE3636-B5FC-4173-98C8-C11A72C3A666

Q28475004-BC085F0D-BD2A-4C74-8EEE-626E1DF0EF5E

Q28475004-ECE56479-D9F6-4BF6-B9BC-6DF224934883

Q28475004-FD548336-D3DA-4844-A279-AB0B17D576C6

P577

Q28475004-665035B8-2E06-43D5-A76C-72009D40419C

P5875

Q28475004-3F69D599-1CCA-4EBC-A0F1-9613022D8E91

P698

Q28475004-312D9FB0-D8FC-40B9-B8D8-57C7F1351A15

P921

Q28475004-EA91A792-42DD-4162-BC5C-D4DE7A0937BF

P932

Q28475004-1C8A97E4-E88C-4F62-8161-AC863E8A5B28

P3181

P356

JOURNAL.PGEN.1000433

P1433

P1476

A genome-wide association stud ...... determinants of warfarin dose

@en

P2093

Anders Rane

http://www.w3.org/2001/XMLSchema#string

Fumihiko Takeuchi

http://www.w3.org/2001/XMLSchema#string

Jonatan Lindh

http://www.w3.org/2001/XMLSchema#string

Lennart Holm

http://www.w3.org/2001/XMLSchema#string

Niclas Eriksson

http://www.w3.org/2001/XMLSchema#string

Ralph McGinnis

http://www.w3.org/2001/XMLSchema#string

Stephane Bourgeois

http://www.w3.org/2001/XMLSchema#string

Vasudev Kumanduri

http://www.w3.org/2001/XMLSchema#string

Venkatesh Ranganath

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

A second generation human haplotype map of over 3.1 million SNPs

Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering

PLINK: a tool set for whole-genome association and population-based linkage analyses

Detection of large-scale variation in the human genome

Circular binary segmentation for the analysis of array-based DNA copy number data

Linkage disequilibrium in humans: models and data.

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

Estimating coverage and power for genetic association studies using near-complete variation data.

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

P304

e1000433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

984680

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PGEN.1000433

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

William M McLaren

Pamela Whittaker

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24214249

http://www.w3.org/2001/XMLSchema#string

P698

19300499

http://www.w3.org/2001/XMLSchema#string

P921

genome-wide association study

P932

2652833

http://www.w3.org/2001/XMLSchema#string